Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
10,880 total articles
Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, announced its participation in two major investor events in May 2026: the H.C. Wainwright 4th Annual BioConnect Investor Conference and the 2026 Stifel Virtual Targeted Oncology Forum. The company will provide webcast presentations and offer one-on-one meetings for i…
SAB Biotherapeutics announced Q1 2026 financial results and highlighted ongoing enrollment in their registrational Phase 2b SAFEGUARD trial of SAB-142 for type 1 diabetes. The company reported encouraging Phase 1 data showing C-peptide preservation and better glycemic control, secured $95 million from a public offering to fund operations through 20…
Sagimet Biosciences reported strong first quarter 2026 financial results, highlighted by securing $175 million in equity financing to fund operations through 2028. The company announced plans to initiate a Phase 3 clinical trial of its novel acne drug denifanstat in the U.S. in the second half of 2026, targeting moderate to severe acne. Ongoing Pha…
BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for encaleret, a targeted treatment for autosomal dominant hypocalcemia type 1 (ADH1). The Phase 3 CALIBRATE trial met all primary and key secondary endpoints, demonstrating rapid and durable improvements in calcium regulation and a favorable safety profile. Encaleret may receiv…
Zevra Therapeutics, a commercial-stage biopharmaceutical company focused on rare diseases, announced its executive team will present at the H.C. Wainwright BioConnect Investor Conference to discuss the company's progress and strategic outlook. The presentation underscores Zevra's commitment to advancing its pipeline and broadening patient access to…
Nayax Ltd. announced robust financial results for Q1 2026, reporting a 32% increase in revenue to $106.9 million, organic revenue growth of 26%, and a 43% year-over-year increase in adjusted EBITDA to $13.9 million. The company expanded its installed base to over 1.5 million devices and customer base to 120,000, demonstrating successful scale and r…
TransUnion's latest report reveals that the median age of renters has risen to 40, with many delaying or foregoing homeownership due to economic factors. This demographic shift presents a strategic growth opportunity for insurers, as these renters demonstrate stable incomes, strong credit profiles, and increasing demand for comprehensive insurance …
POET Technologies Inc., a Nasdaq-listed company specializing in integrated optical engines and light sources for AI networks, announced the appointment of Sandeep Kumar as Chief Operating Officer. Dr. Kumar brings extensive semiconductor operations experience from Silicon Labs and other industry leaders. His immediate focus will be on preparing POE…
Hub Group, Inc. has filed a Notification of Late Filing for its quarterly report and disclosed delays in its annual report due to identified accounting inaccuracies requiring restatement of financials for 2023, 2024, and part of 2025. Despite operational growth in intermodal and logistics, brokerage volume declined as the company focuses on profita…
Arvinas, Inc. announced FDA approval of VEPPANU™ (vepdegestrant), the first PROTAC therapy approved for treating ESR1-mutated, ER+/HER2- advanced breast cancer, marking a milestone for the company and the PROTAC modality. The company reported strong clinical progress in its pipeline including positive Phase 1 data for ARV-102 in Parkinson’s disease…
Achieve Life Sciences announced key senior appointments to its board and commercial team, including executives from Verona Pharma, signaling a strong push towards commercializing cytisinicline, a novel treatment for nicotine dependence with FDA review anticipated in June 2026. These leadership additions come shortly after a substantial $354 million…
NeurAxis, Inc. reported a record first quarter for 2026 with revenues up 80% year-over-year to $1.6 million driven by the implementation of the Category I CPT code for their IB-Stim device. The company expanded gross margin and reduced operating losses while securing significant regulatory and commercial milestones including Veterans Affairs contra…
Unicycive Therapeutics announced its first quarter 2026 financial results alongside an optimistic update on the FDA review process for oxylanthanum carbonate (OLC), a novel phosphate binder targeting hyperphosphatemia in chronic kidney disease dialysis patients. The company highlighted its preparedness for a potential product launch following a Jun…
CorVel Corporation will host a live webcast on May 20, 2026, to discuss its quarterly and fiscal earnings, featuring its CEO and CFO. The webcast will include insights into financial performance, strategic initiatives, and a Q&A session. The company highlights its focus on technology-driven risk management solutions in healthcare-related sectors.
Prelude Therapeutics reported Q1 2026 financial results highlighting progress in its oncology pipeline including initiation of a Phase 1 study for PRT12396, a mutant-selective JAK2V617F inhibitor, advancement of PRT13722, a selective oral KAT6A degrader for ER+ breast cancer, and development of novel degrader antibody conjugates. The company extend…
Cartesian Therapeutics, a late-stage clinical biotechnology company focused on cell therapy for autoimmune diseases, announced it will participate in a fireside chat at the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference. The company will discuss its lead CAR-T therapy asset, Descartes-08, currently in various clinical trial phas…
Acumen Pharmaceuticals reported its Q1 2026 financial results and business highlights, emphasizing ongoing progress in its Phase 2 ALTITUDE-AD study for sabirnetug (ACU193), a novel Alzheimer's treatment targeting toxic amyloid beta oligomers. The company expects topline results by late 2026 and plans for an IND filing mid-2027 for its enhanced bra…
C4 Therapeutics reported progress in developing cemsidomide as a foundational multiple myeloma treatment, initiated multiple clinical trials, and expanded its partnership with Roche to develop degrader-antibody conjugates. The company maintains a strong cash position with a runway to the end of 2028, despite a net loss in Q1 2026. Upcoming trial da…
eToro Group Ltd. announced its first quarter 2026 results showing solid financial growth with net contribution rising 19% year-over-year to $258 million and net income up 37% to $82 million. The company expanded product offerings including 24/7 trading for commodities and equities, AI-powered tools, and launched crypto trading in New York. The acqu…
Cal-Maine Foods, Inc., the largest U.S. egg producer, announced the acquisition of the Van's Foods brand from Sara Lee Frozen Bakery. This strategic purchase aims to diversify Cal-Maine's portfolio by entering the better-for-you frozen breakfast segment, expanding prepared foods sales by an estimated 10% annually, and enhancing distribution across …
Colliers International’s U.S. Engineering division is partnering with Oklahoma City-based engineering firm Frankfurt-Short-Bruza Associates (FSB) to establish a national aviation practice and enhance capabilities in federal, mission-critical, and Native American sectors. The partnership will allow Colliers Engineering to access the high-barrier avi…
Olema Pharmaceuticals reported Q1 2026 financials and operational progress, emphasizing upcoming Phase 3 trial results for palazestrant (OPERA-01) expected in fall 2026 and ongoing enrollment in OPERA-02. The company also highlighted initial clinical data for OP-3136 to be presented at ASCO. With over $505 million in cash and expanding clinical pro…
Lantronix Inc. has introduced the xPico 600 series, a production-ready embedded gateway module featuring dual-band Wi-Fi 6, Bluetooth Low Energy 5.4, enterprise-grade security, and integration with their Percepxion cloud platform for zero-touch provisioning and remote device management. Designed to accelerate IoT product development and simplify de…
Seres Therapeutics, a clinical-stage biotechnology company focused on live biotherapeutics, announced its participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference, where it will present a company overview. The company is advancing several therapies, including SER-155 and SER-603, targeting inflammatory and immune diseases.
American Shared Hospital Services (AMS), a U.S.-based provider of advanced cancer treatment equipment and services through leasing and patient care segments, announced its first quarter 2026 financial results will be released ahead of a May 14th conference call. The company outlined plans to discuss growth and expansion in Gamma Knife, proton thera…
